Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Payables (2018 - 2025)

Historic Payables for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $3.6 million.

  • Exagen's Payables rose 22208.14% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 22208.14%. This contributed to the annual value of $4.1 million for FY2024, which is 3213.03% up from last year.
  • As of Q3 2025, Exagen's Payables stood at $3.6 million, which was up 22208.14% from $2.5 million recorded in Q2 2025.
  • Exagen's Payables' 5-year high stood at $4.5 million during Q1 2025, with a 5-year trough of $1.1 million in Q3 2024.
  • Moreover, its 5-year median value for Payables was $2.5 million (2021), whereas its average is $2.6 million.
  • As far as peak fluctuations go, Exagen's Payables tumbled by 5784.22% in 2023, and later skyrocketed by 22208.14% in 2025.
  • Exagen's Payables (Quarter) stood at $2.5 million in 2021, then increased by 22.23% to $3.0 million in 2022, then grew by 2.79% to $3.1 million in 2023, then surged by 32.13% to $4.1 million in 2024, then decreased by 13.97% to $3.6 million in 2025.
  • Its Payables stands at $3.6 million for Q3 2025, versus $2.5 million for Q2 2025 and $4.5 million for Q1 2025.